Alemtuzumab Biosimilar
Hematologic Malignancies
Phase 3Active
Key Facts
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group is a leading Chinese pharmaceutical company with a diversified portfolio spanning innovative drug development, generic medicines, and pharmaceutical manufacturing. Founded in 1997 and publicly traded on the Hong Kong Stock Exchange, the company has established itself as a major player in China's pharmaceutical industry with strong R&D capabilities and extensive manufacturing infrastructure. CSPC focuses primarily on oncology, CNS disorders, and metabolic diseases, with multiple products in clinical development and a robust commercial portfolio serving both domestic and international markets.
View full company profileOther Hematologic Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1905 | Jiangsu Hengrui Medicine | Phase 1 |
| Rituximab biosimilar (IBI301) | Innovent Biologics | Approved |
| Lead CAR-T Program | Arcellx | Phase 1 |
| KT-333 | Kymera Therapeutics | Phase 1 |
| Undisclosed CAR-T programs | Beam Therapeutics | Discovery/Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| Trichostatin A (TSA) | Vanda Pharmaceuticals | Oncology Program |
| Cord Blood HSC Unit | Global Cord Blood | Approved/Commercial |
| TSC-102-A01 | TScan Therapeutics | Preclinical |
| TSC-102-A03 | TScan Therapeutics | Preclinical |
| LBL-007 | LakeShore Biopharma | Phase 1 |
| CER-T Cell Platform | CERo Therapeutics | Pre-clinical |